Novel algorithms for diagnosing heart failure with preserved ejection fraction in patients with hypertension and obesity
https://doi.org/10.15829/1728-8800-2021-2569
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome associated with frequent hospitalizations, high mortality rates, and an absence of proven effective therapy. This type of heart failure is often accompanied by comorbidity that complicate the diagnosis of the underlying disease. The algorithm developed in 2016 does not take into account the heterogeneity of patients and course of HFpEF. Recently, new diagnostic algorithms (H2FPEF, HFA-PEFF) and biomarkers have appeared that allow detecting HFpEF at an early stage, taking into account the pathogenesis, which may contribute to development of new effective treatment methods.
About the Authors
Yu. A. Vasyuk
Moscow State University of Medicine and Dentistry
Russian Federation
Yury Aleksandrovich Vasyuk
Russian Federation
Yury Aleksandrovich Vasyuk
E. Yu. Shupenina
Moscow State University of Medicine and Dentistry
Russian Federation
Elena Yurievna Shupenina
Russian Federation
Elena Yurievna Shupenina
G. A. Namazova
Moscow State University of Medicine and Dentistry
Russian Federation
Gulnar Adilovna Namazova
Russian Federation
Gulnar Adilovna Namazova
T. I. Dubrovskaya
Moscow State University of Medicine and Dentistry
Russian Federation
Tatiana Igorevna Dubrovskaya
Russian Federation
Tatiana Igorevna Dubrovskaya
References
1. Ul Haq M, Wong C, Hare D. Heart failure with preserved ejection fraction: an insight into its prevalence, predictors, and implications of early detection. Rev Cardiovasc Med. 2015;16(1):20-7.
2. van Riet E, Hoes A, Wagenaar K, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18(3):242-52. https://doi.org/10.1002/ejhf.483.
3. Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russ J Cardiol. 2016;8(136):7-13. (In Russ.) https://doi.org/10.15829/1560-4071-2016-8-7-13.
4. Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. https://doi.org/10.1002/ejhf.592.
5. Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(s6):8-164. (In Russ.) https://doi.org/10.18087/cardio.2475.
6. Venkatesh Y, Anjan M, Loftus M, et al. Prevalence, clinical phenotype and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110(6):870-6. https://doi.org/10.1016/j.amjcard.2012.05.014.
7. Roberts E, Ludman A, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910. https://doi.org/10.1136/bmj.h910.
8. Nagueh S, Smiseth O, Appleton C, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277-314. https://doi.org/10.1016/j.echo.2016.01.011.
9. Caballero L, Kou S, Dulgheru R, et al. Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. Eur Heart J Cardiovasc Imaging. 2015;16:1031-41. https://doi.org/10.1093/ehjci/jev083.
10. Reddy Y, Carter R, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138(9):861-70. https://doi.org/10.1161/CIRCULATIONAHA.118.034646.
11. Sueta D, Yamamoto E, Nishihara T, et al. H2FPEF score as a prognostic value in HFpEF patients. Am J Hypertens. 2019;32(11):1082-90. https://doi.org/10.1093/ajh/hpz108.
12. Mareev YuV, Garganeeva AA, Tukish OV, et al. Difficulties in diagnosis of heart failure with preserved ejection fraction in clinical practice: dissonance between echocardiography, NTproBNP and H2HFPEF score. Kardiologiia. 2019;59(12S):37-45. (In Russ.) https://doi.org/10.18087/cardio.n695.
13. Pieske B, Tshope K, de Boer R, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic 24. algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297-317. https://doi.org/10.1093/eurheartj/ehz641.
14. Gorter T, van Veldhuisen D, Bauersachs J, et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:16-37. https://doi.org/10.1002/ejhf.102.
15. Voigt J, Pedrizzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015;16:1-11. https://doi.org/10.1016/j.echo.2014.11.003.
16. Shah A, Claggett B, Kitzman D, et al. Contemporary assessment of left ventricular diastolic function in older adults: the atherosclerosis risk in communities study. Circulation. 2017;135:426-39. https://doi.org/10.1161/CIRCULATIONAHA.116.024825.
17. Chow S, Maisel A, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017;135:e1054-91. https://doi.org/10.1161/CIR.0000000000000490.
18. Meijers W, Hoekstra T, Jaarsma T, et al. Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Neth Heart J. 2016;24:287-95.
19. Obokata M, Kane G, Reddy Y, et al. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation. 2017;135:825-38. https://doi.org/10.1161/CIRCULATIONAHA.116.024822.
20. Lancellotti P, Pellikka P, Budts W, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2016;17:1191-229. https://doi.org/10.1093/ehjci/jew190.
21. Obokata M, Borlaug B. The strengths and limitations of E/e’ in heart failure with preserved ejection fraction. Eur J Heart Fail. 2018;20:1312-4. https://doi.org/10.1002/ejhf.1250.
22. Ovchinnikov AG, Ageev FT, Alekhin MN, et al. Diastolic transthoracic echocardiography with incremental work load in the evaluation of heart failure with preserved ejection fraction: indications, methodology, interpretation. US and Funct Diagn. 2020;2:60-90. (In Russ.) https://doi.org/10.24835/1607-0771-2020-2-60-90.
23. van Riel A, Opotowsky A, Santos M, et al. Accuracy of echocardiography to estimate pulmonary artery pressures with exercise: a simultaneous invasive-noninvasive comparison. Circ Cardiovasc Imaging. 2017;10:e005711. https://doi.org/10.1161/CIRCIMAGING.116.005711.
24. Dorfs S, Zeh W, Hochholzer W, et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3103-12. https://doi.org/10.1093/eurheartj/ehu315.
25. 25 Ferreira V, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72:3158-76. https://doi.org/10.1016/j.jacc.2018.09.072.
26. Song Y, Li F, Xu Y, et al. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2020;304:95-100. https://doi.org/10.1016/j.ijcard.2020.01.039.
27. Cui Y, Qi X, Huang A, et al. Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction. Med Sci Monit. 2018;24:5139-46. https://doi.org/10.12659/MSM.908840.
28. Edelmann F, Holzendorf V, Wachter R, et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2015;17:214-23. https://doi.org/10.1002/ejhf.203.
29. Hage C, Mihf^lsson E, Linde C, et al. Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction. Circ Cardiovasc Genet. 2017;10:1-35. https://doi.org/10.1161/CIRCGENETICS.116.001633.
30. Watson CJ, Gupta S, O’Connell E, et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015;17:405-15. https://doi.org/10.1002/ejhf.244.
Supplementary files
Review
For citations:
Vasyuk Yu.A., Shupenina E.Yu., Namazova G.A., Dubrovskaya T.I. Novel algorithms for diagnosing heart failure with preserved ejection fraction in patients with hypertension and obesity. Cardiovascular Therapy and Prevention. 2021;20(1):2569. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2569
Views:
2419
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Email this article 
